Literature DB >> 9503270

Increased synaptic availability of norepinephrine following desipramine is not essential for increases in GR mRNA. Short communication.

A Eiring1, F Sulser.   

Abstract

Male Sprague-Dawley rats were treated for 7 days with the norepinephrine (NE) uptake inhibitors desipramine (DMI) or (+)-oxaprotiline or the inactive (-)-enantiomer of oxaprotiline. DMI, as previously reported, significantly increased hippocampal glucocorticoid receptor (GR) mRNA while the equipotent NE uptake inhibitor (+)-oxaprotiline like the inactive (-)-oxaprotiline did not alter hippocampal levels of GR mRNA. The results indicate that an increase in the synaptic availability of NE as a consequence of uptake inhibition is not responsible for the action of DMI on GR gene expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9503270     DOI: 10.1007/BF01294725

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  10 in total

1.  Increased glucocorticoid receptor gene promoter activity after antidepressant treatment.

Authors:  M C Pepin; M V Govindan; N Barden
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

2.  Stereospecificity of behavioural and biochemical responses to oxaprotiline--a new antidepressant.

Authors:  A Delini-Stula; K Hauser; P Baumann; H R Olpe; P Waldmeier; A Storni
Journal:  Adv Biochem Psychopharmacol       Date:  1982

3.  Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer.

Authors:  P C Waldmeier; P A Baumann; K Hauser; L Maitre; A Storni
Journal:  Biochem Pharmacol       Date:  1982-06-15       Impact factor: 5.858

4.  Oxaprotiline: induction of central noradrenergic subsensitivity of its (+)-enantiomer.

Authors:  R Mishra; D D Gillespie; R A Lovell; R D Robson; F Sulser
Journal:  Life Sci       Date:  1982-05-17       Impact factor: 5.037

5.  Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo.

Authors:  J R Seckl; G Fink
Journal:  Neuroendocrinology       Date:  1992-06       Impact factor: 4.914

6.  Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant.

Authors:  S P Rossby; I Nalepa; M Huang; C Perrin; A M Burt; D E Schmidt; D D Gillespie; F Sulser
Journal:  Brain Res       Date:  1995-07-31       Impact factor: 3.252

7.  Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla.

Authors:  I Kitayama; A M Janson; A Cintra; K Fuxe; L F Agnati; S O Ogren; A Härfstrand; P Eneroth; J A Gustafsson
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  The 'serotonin/norepinephrine link' beyond the beta adrenoceptor.

Authors:  A Eiring; D H Manier; P R Bieck; R D Howells; F Sulser
Journal:  Brain Res Mol Brain Res       Date:  1992-12

9.  Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain.

Authors:  A Peiffer; S Veilleux; N Barden
Journal:  Psychoneuroendocrinology       Date:  1991       Impact factor: 4.905

10.  The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus.

Authors:  B Budziszewska; J Siwanowicz; E Przegaliński
Journal:  Pol J Pharmacol       Date:  1994 May-Jun
  10 in total
  2 in total

1.  Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters.

Authors:  C M Pariante; A Makoff; S Lovestone; S Feroli; A Heyden; A H Miller; R W Kerwin
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Patterns of sequence conservation in presynaptic neural genes.

Authors:  Dexter Hadley; Tara Murphy; Otto Valladares; Sridhar Hannenhalli; Lyle Ungar; Junhyong Kim; Maja Bućan
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.